Related Experiment Videos
Urinary excretion of cyclic guanosine 3'.5'-monophosphate in children with malignant tumours
Insights
Children with malignant tumors or lymphomas show elevated urinary cyclic guanosine 3'.5'-monophosphate (cyclic GMP) excretion. Levels decrease during remission and rise again with recurrence, indicating cyclic GMP
Area of Science:
- Pediatric Oncology
- Biochemistry
- Cancer Biomarkers
Background:
- Malignant tumors and lymphomas are significant health concerns in children.
- Identifying reliable biomarkers for cancer detection and monitoring is crucial.
- Cyclic guanosine 3".5"-monophosphate (cyclic GMP) is a key intracellular second messenger.
Purpose of the Study:
- To investigate urinary cyclic GMP excretion rates in pediatric cancer patients.
- To assess the correlation between cyclic GMP levels and disease status (active disease, remission, recurrence).
Main Methods:
- Measurement of urinary cyclic GMP excretion rates in children across various age groups.
- Comparison of cyclic GMP levels between children with malignant conditions and healthy controls (implied).
- Longitudinal follow-up of cyclic GMP levels during different phases of cancer treatment (up to three years).
Main Results:
- Significantly increased urinary cyclic GMP excretion was observed in 79% of children with malignant tumors or lymphomas.
- Urinary cyclic GMP levels decreased to near-normal values during periods of disease remission.
- Recurrences of the malignant disease were associated with a subsequent increase in cyclic GMP excretion.
Conclusions:
- Urinary cyclic GMP may serve as a potential biomarker for malignant tumors and lymphomas in children.
- Changes in urinary cyclic GMP levels correlate with the clinical status of pediatric cancer patients.
- Further research is warranted to explore the diagnostic and prognostic utility of cyclic GMP in pediatric oncology.
Abstract:
The present study shows an increased urinary cyclic guanosine 3'.5'-monophosphate (cyclic GMP) excretion rate in children of all age groups bearing malignant tumours or lymphomas. The incidence of increased cyclic GMP excretion was highly significant (79%). Follow-up studies of up to three years have revealed that during periods of remission of malignant disease the urinary cyclic GMP excretion drops to near normal values, whereas recurrences are accompanied by a new increase of cyclic GMP excretion.